The EMG GOLD Podcast

The EMJ GOLD podcast is back for a new season! In the first episode of season 10, the team are joined by Dheepa Chari, Vice President and Head of Global Scientific Communications, GSK, to discuss the past, present and future of scientific communications. Together, Dheepa and Isabel explore her journey from biostatistics to biopharma leadership — and the lessons learned along the way. They discuss what great science communication looks like, where it's heading next and why storytelling still matters in a digital-first world. Plus, expect practical insights on cross-functional collaboration and the growing role of AI. A little more on EMJ GOLD's guest… Dheepa Chari is the Vice President and Head of Global Scientific Communications at GSK. Here, she leads strategy and execution across Oncology, Vaccines, Specialty Care and General Medicine, driving innovation in how scientific narratives are delivered across channels. Before joining GSK in 2024, Dheepa held senior posts at Pfizer, Amgen and Novartis in both clinical and communications roles. Outside of work, Dheepa brings stories to life in a different way - as a singer-songwriter who regularly performs in New York City.

Season 10 is on the horizon, but before we release our first episode, why not tune in to some of Isabel and Jade's favourite moments from season 9?  From leadership insights from top CEOs to navigating setbacks in R&D, there's plenty to discover in this season's batch of GOLD Medal Moments.   As well as the EMJ GOLD team, you'll hear from four former guests:  Charl van Zyl, CEO, Lundbeck Pharmaceuticals  Dr Dennise Broderick, President and Managing Director, Galen Pharma  Rebecca Vermeulen, recipient of the Healthcare Businesswomen's Association (HBA) STAR award for 2025  Christoph von der Goltz, Global Head of Medicine Central Nervous System and Emerging Areas, Boehringer Ingelheim 

Join Isabel and Jade as they wrap up Season 9 of the podcast with special guest Dennise Broderick, President and Managing Director, Galen Pharma.  In this episode, Jade and Dennise discuss her move from academia to the pharmaceutical industry, her lifelong ambition to be a leader and how she approaches hard decisions in business.  A little more on EMJ GOLD's guest… Dennise is Managing Director and President at Galen – a pharmaceutical company based in Northern Ireland focused on pain management, dermatology and gastroenterology. There, she is responsible for all the aspects of the company's operations, marketing and governance across its various sites throughout the UK and Europe. Previously, Dennise has held positions at Pfizer, Hospira, Zeneus and Viatris – most recently working as the Country Manager at Ipsen. 

How can pharmaceutical companies best navigate setbacks in drug development to deliver breakthroughs in R&D? Find out in this week's episode, where Isabel and Jade share an interview with Christoph von der Goltz, Global Head of Medicine Central Nervous System and Emerging Areas, Boehringer Ingelheim.  Together, he and Jade explore the ins and outs of drug failure, whether to pivot or persevere after an R&D setback, how to better break the stigma of mental illness and much more.  A little more on EMJ GOLD's guest…  Christoph von der Goltz is Global Head of Medicine Central Nervous System and Emerging Areas at Boehringer Ingelheim. He has more than 15 years of experience in a variety of roles in pharmaceutical R&D. He is also a board-certified psychiatrist with more than 10 years of clinical experience in neurology and psychiatry and academic research in preclinical, clinical and public health projects in Germany and Sweden. 

Join Isabel and Jade this week as they delve into lessons in leadership and patient centricity with Rebecca Vermeulen, recipient of the Healthcare Businesswomen's Association (HBA) STAR award for 2025.  Rebecca shares her journey from pharmacist to industry leader, discussing her approach to leadership, the current landscape for women in pharma and what effective patient centricity looks like in practice.  A little more on EMJ GOLD's guest  Rebecca was recently awarded the STAR prize by the Healthcare Businesswomen's Association in recognition of her outstanding contributions to the organisation's growth, influence and impact. Her win highlights her leadership, particularly during her time as the HBA Global Board Chair throughout the pandemic.   She has spent over 30 years working in the industry and has served in a variety of functions including medical affairs, clinical research, sales and medical communications. 

Join Isabel and Jade as they uncover how AI is shaking up the radiology space and beyond with Naiara Martínez Cabrera, Vice President, Global Marketing, DeepHealth.  Together, Naiara and Jade explore what first drew the marketing leader to the healthcare sector, why radiology in particular has seen such a boost from artificial intelligence, what other therapy areas can learn from space and much more. A little more on EMJ GOLD's guest… Naiara Martínez Cabrera is Vice President of Global Marketing, DeepHealth, where she has been since the company's inception in 2023. Prior to this appointment, she worked at Philips in roles such as Head of Communications and Head of Downstream Marketing for Precision Diagnosis.

This week, join Isabel and Jade as they explore what's on the horizon for cardiac care, focusing on the revolutionary impact of remote monitoring with Angelo Auricchio, Chief Medical Officer, Rhythm Management, Boston Scientific.  He and Isabel discuss Angelo's recent career change into the industry, how technology could reform the UK's NHS, the role of remote monitoring in patient wellbeing and more.  A little more on EMJ GOLD's guest… Angelo Auricchio was appointed Chief Medical Officer, Rhythm Management, Boston Scientific in September 2024, where he works across the EMEA region. Prior to his time in industry, he gained a wealth of experience in academia and medicine, serving as Editor-in-Chief of the European Society of Cardiology's journal EP Europace and President of the European Heart Rhythm Association.    During his time in the medical field, he also served as Deputy Head of the Cardiology Department and Director of the Clinical Electrophysiology Unit at the Istituto Cardiocentro Ticino in Switzerland.   

Join Isabel and Jade as they explore the persistent misunderstandings of women's health in modern medicine with Mary Stutts, CEO of the Healthcare Businesswomen's Association.  In this episode, Mary unpacks the key findings of the HBA's latest report, which exposes critical gaps in doctors' understanding of women's health. She discusses the root causes, the real-world consequences and what the pharmaceutical industry must do to drive meaningful change.  A little more on EMJ GOLD's guest…  Mary is the CEO of the HBA, a global organisation with a mission is to promote the advancement and impact of women in healthcare. She is a leading voice in the industry, advocating for inclusive leadership, representative workforces and health equity. Prior to joining the HBA, she worked for Genentech, Bristol Myers Squibb, Bayer and other pharmaceutical organisations.   She is also an accomplished author, having published her books ‘Recurring Themes of Exclusion in the Workplace' and ‘The Missing Mentor: Women Advising Women on Power, Progress and Priorities'. 

Why do we forget? Join Isabel and Jade as they explore the science behind memory, recall and retention, and uncover why interactive content could be the key to making information stick. In this episode, discover how interactivity enhances learning, helps HCPs recognise the value of new therapies and ultimately improves patient care. Read our article exploring the topic further here. And if you're interested to see how interactive works in the medical context, check out the interactive article mentioned here.

Join Isabel and Jade for part two of their World Cancer Day special for 2025, where guest Martin Price, Vice President, Health Economics, Market Access and Reimbursement, EMEA, Johnson & Johnson, uncovers more of his insights into the oncology space.  In this instalment, Martin shares his thoughts on improving access to innovative cancer medicines, improving public trust toward the industry and his personal leadership style.  A little more on GOLD's guest… Martin Price is Vice President for Health Economics, Market Access and Reimbursement in Europe, the Middle East and Africa, Johnson & Johnson, a role he has held for the past eight years. He leads the teams responsible for achieving optimal and accelerated market access, at a fair and value-based price, for Johnson & Johnson's new products and indications. Prior to this, Price worked in Johnson & Johnson's UK affiliate, latterly as director of external affairs, where he was responsible for market access, communications and government affairs. He joined Johnson & Johnson in 2001 from GlaxoSmithKline, where he began his career as senior health-outcomes manager. 

Join Isabel and Jade as they present a special World Cancer Day 2025 edition of the podcast. They are joined by Martin Price, Vice President, Health Economics, Market Access and Reimbursement, EMEA, Johnson & Johnson.  In this first instalment of the conversation, Martin and Jade discuss this year's theme ‘United by Unique', the increasing importance of real-world evidence in oncology and improving access to innovative cancer medicines.   A little more on GOLD's guest… Martin Price is Vice President for Health Economics, Market Access and Reimbursement in Europe, the Middle East and Africa, Johnson & Johnson, a role he has held for the past eight years. He leads the teams responsible for achieving optimal and accelerated market access, at a fair and value-based price, for Johnson & Johnson's new products and indications. Prior to this, Price worked in Johnson & Johnson's UK affiliate, latterly as director of external affairs, where he was responsible for market access, communications and government affairs. He joined Johnson & Johnson in 2001 from GlaxoSmithKline, where he began his career as senior health-outcomes manager.

The EMJ GOLD podcast is back for a new season! In the first episode of Season 9, the team are welcomed by Charl van Zyl, President and CEO, Lundbeck Pharmaceuticals, to discuss advances in the treatment of neurological disorders, making this the 'decade of the brain', and how industry can do more to support patients living brain conditions.  Together, Charl and Isabel explore his career journey in the pharmaceutical industry, Lundbeck's plans for the future, the role of digital health technology and much more.  A little more on EMJ GOLD's guest...  Charl van Zyl joined Lundbeck as President and CEO in September 2023. He brings more than 23 years of experience from commercial international management roles within the pharmaceutical industry, most recently in the field of immunology and neurology from UCB where he served as Executive Vice President and Head of Neurology globally, responsible for corporate activities in Europe and international markets.  Charl is British and holds a degree in Medical Biochemistry from the University of Cape Town, South Africa. He has lived and worked in South Africa, United States, Japan, Switzerland, Belgium and now Denmark. 

Curious to discover what might lie ahead for industry in 2025? Join Isabel and Jade in this special episode of the EMJ GOLD podcast as they reflect on whether last year's predictions for 2024 came true, while three special guests share their predictions and hopes for pharma in the year ahead.  The line-up includes Jennifer Schranz of Ipsen, Mercedes Diz of Almirall and EMJ's own Dr Jonathan Sackier - all of whom share their predictions in their areas of expertise.  A little more on GOLD's guests…  Jennifer Schranz is the Senior Vice President, Global Head of Rare Diseases at Ipsen, where she oversees the Rare Diseases therapy area with a focus on R&D strategy and execution. During her time at the business, she has led talented teams of scientists and fostered strong internal collaborations within the company, leveraging her clinical development expertise to advance Ipsen's vision of addressing challenging rare diseases.  Mercedes Diz has over 20 years' experience in the pharmaceutical industry, having graduated with a degree in Biochemistry and Molecular Biology from the Autonomous University of Madrid. She has worked in a number of different pharmaceutical companies, from J&J to Pfizer, and is also a keen member of the Healthcare Businesswomen's Association. At Almirall, she leads portfolio strategy and commercial innovation for global brands, new products and digital and cultural transformation.  Dr Jonathan Sackier is Chairman at EMJ and the host of the EMJ podcast, where he utilises his experience as a physician to discuss the latest breakthroughs and challenges in the medical field with fellow practitioners and experts. Jonathan is a founding partner of many start-ups in the medical technology space and created the world's first operating room robot. 

As 2024 comes to a close, it's time to look back on a year in the pharmaceutical industry. In this final episode of the year, Isabel and Jade are joined by three former guest to reflect on the pivotal moments that defined the past 12 months. They are joined by Jennifer Schranz from Ipsen, Martina Dempsey from Astellas and Elias Revonta, CEO of Orcason, who all return to the podcast to share their insights. Together, they'll discuss the major trends, challenges and breakthroughs that shaped 2024, including advancements in oncology, gene therapy, rare diseases and the growing role of AI. A little more on EMJ GOLD's guests... Jennifer Schranz is the Senior Vice President, Global Head of Rare Diseases at Ipsen, where she oversees the Rare Diseases therapy area with a focus on R&D strategy and execution. During her time at the business she has led talented teams of scientists and fostered strong internal collaborations within the company, leveraging her clinical development expertise to advance Ipsen's vision of addressing challenging rare diseases. Martina Dempsey is the Vice President of Commercial Strategy & Operations at Astellas Europe, having worked with the business since 2014 in her home country of Ireland. In addition to her role at the pharma company, she also acts as a Board Member for the Irish Pharmaceutical Healthcare Association. Prior to her time at Astellas, she spent 13 years at GSK in various roles including in the regulatory affairs and business transformation sectors. Elias Revonta is the Founder and CEO, Orcason Medical, where he is supported by a strong background in the medical device industry – spanning over 20 years in various leadership roles from sales to product development. He is passionate about transforming and democratising healthcare with modern and easy-to-use diagnostic tools that serve all demographics.

In this final episode of the season, Isabel discusses how to normalise the conversation, not the suffering, around menopause with Dr Cecilia Caetano, Vice President, Head, Global Medical Affairs, Women's Health, Bayer. Menopause affects over 50% of the world's population, but its symptoms and effects are often misunderstood or ignored. Find out how industry can help by equipping not only HCPs but also women with the knowledge and awareness to manage menopause on an individual level, debunking the myths and prejudices surrounding the topic and much more.

Season 8 is almost over, but before we release our finale episode, why not take a listen to some of our favourite moments from the last couple of months? From an insight into why Gen Z might be turning their sails towards the pharmaceutical industry, to a call for a better understanding of HIV stigma, there's plenty to discover in this season's GOLD Medal Moments.

In this episode of the EMJ GOLD podcast, Jade and Isabel explore one of the most urgent global health issues: antimicrobial resistance (AMR). As part of World AMR Awareness Week, they are highlighting this year's theme ‘Educate. Advocate. Act now'. Joining the conversation is Elias Revonta, Founder and CEO, Orcason Medical, who shares his vision for tackling AMR through groundbreaking medical technology. Orcason Medical is pioneering point-of-care devices for ear, nose and throat conditions to address the overprescription of antibiotics—a vital measure in the fight against AMR. A little more on GOLD's guest… Elias Revonta is the Founder and CEO, Orcason Medical, where he is supported by a strong background in the medical device industry – spanning over 20 years in various leadership roles from sales to product development. He is passionate about transforming and democratising healthcare with modern and easy-to-use diagnostic tools that serve all demographics. With a mission to combat the rise of AMR, his goal is to protect the power of antibiotics and improve the lives of millions of patients by enabling smarter, safer healthcare solutions.

In this episode, Isabel welcomes Patrick Oliver, General Manager for the UK and Ireland at Alfasigma, to explore the company's exciting entry into the UK market and the evolving landscape of healthcare in the country.   In the conversation, Patrick brings his wealth of industry experience to share his vision for Alfasigma's future, the potential he sees in the UK healthcare market and the unique challenges ahead. They also delve into Lord Darzi's report on the NHS, examining its implications for healthcare reform and innovation.  A little more on GOLD's guest…  Patrick Oliver is Alfasigma's General Manager for the UK & Ireland, a role he's held since the company's launch in the UK in early 2024. He has 36 years' experience in the industry, with 16 years specifically in market access. Prior to joining Alfasigma, Patrick worked in market access for a number of large pharmaceutical companies including Johnson & Johnson, AbbVie and Abbott. 

As 2024 draws to a close, what should pharma teams be focusing their budgets on for the final quarter of the year? Join Jade and Isabel as they explore the critical trends that have shaped the industry in 2024. As teams finalise their budgets and plan for the final quarter and year ahead, this conversation brings insights into how strategies like personalised engagement, thought leadership and interactive, on-demand content are making an impact. With real-life examples, learn about the tools you can invest in to end the year on a high.  

In this new episode, the team welcomes Jennifer Schranz, Senior Vice President, Global Head of Rare Diseases, Ipsen, to investigate the burden faced by women with rare diseases. Together, Jennifer and Jade discuss how the industry can address challenging rare diseases and making a meaningful impact on patients' lives, the double jeopardy that women with rare diseases face, recent breakthroughs in the space and much more.

In the latest episode of our podcast, we welcome Richard Lowenthal, CEO, ARS Pharmaceuticals, to explore the company's mission to address unmet needs in allergy care. During the conversation, Richard shares insights into his early career at the FDA and the regulatory challenges he faced in bringing ARS's new nasal spray to treat severe allergic reactions to market. He also discusses the future direction of the company and much more. A little more on EMJ GOLD's guest… Richard Lowenthal is the co-founder, President, and CEO, ARS Pharmaceuticals, with a leadership role since the company's inception in 2015. Before ARS, he founded Pacific-Link Regulatory Consulting, where he contributed to the development of their diazepam nasal spray. Richard's extensive background includes senior roles at Cadence Pharmaceuticals, Maxim Pharmaceuticals and Janssen Research Foundation, as well as work as a chemist at the FDA. He holds an M.Sc. in organic chemistry and an MSEL and has chaired the American Association of Pharmaceutical Scientists.

In the latest episode, Jade sits down with Martina Dempsey, Vice President of Commercial Strategy and Operations at Astellas Europe, to discuss empowering women in the pharmaceutical industry.  They explore how pharma meets the needs and values of young graduates, the ongoing challenges women face in securing leadership roles, the critical impact of mentorship on career development and much more. 

In this episode, Isabel is joined by Nedim Pipic, Senior Vice President and Global Therapeutic Area Head for Mental Health, Boehringer Ingelheim, to mark World Mental Health Day on 10 October 2024.  Their conversation dives into the unique challenges faced by those living with serious mental illnesses, the impact of media representation and the role pharma can play in transforming treatment and quality of life for these patients.  Central to their discussion is the importance of amplifying lived experiences, a key focus of Boehringer's new campaign, Schizophrenia in Real Life: Stories of Challenges, Resilience, and Hope.  The campaign aims to build greater understanding and acceptance of the condition by highlighting the strength and resilience of those living with it. 

This week, Jean-Bernard Simeon, Senior Vice President and Head, ViiV Healthcare Europe, sits down with the EMJ GOLD team to share his thoughts on the current landscape for patients with HIV in Europe.   Together, JB and Jade explore the UNAIDS roadmap to end the HIV epidemic by 2030, the barriers faced by people living with HIV in Europe, stigmas still surrounding the condition and much more.   

The EMJ GOLD podcast is back! In the first episode of season 8, Jade sits down with Chantal Friebertshäuser, Senior Vice President and General Manager, EMEAC, Moderna, to discuss how Europe can combat the recent erosion of trust in vaccines. Together, the two explore the role of governments in addressing vaccine hesitancy, improving vaccine education amongst various groups, how a culture of collaboration can improve the current vaccine landscape and much more.

The new season of the podcast is only a week away, so before we get started – why not have a listen to some of the best bits from Series 7? From a deep dive into women's health to why the industry thrives on a little healthy competition, there's plenty to discover in last season's highlights. As well as the EMJ GOLD team's analysis of the key themes, you'll hear from six former guests: Mercedes Diz, Chief Marketing Office, Almirall Nichole Davies, Global Chief Strategy Officer, VML Health Edmond Chan, Senior Director, EMEA TA Lead, Haemato-Oncology, J&J Stefan Woxström, Senior Vice President, Europe and Canada, AstraZeneca Danie Du Plessis, EVP, Pharmaceutical Operations, Kyowa Kirin Harmony Garges, Chief Medical Officer ViiV Healthcare.

In this season finale of the EMJ GOLD podcast, Isabel speaks to Dr Tadaaki Taniguchi, Chief Medical Officer, Head of Medical and Development, Astellas Pharma, about how he strives to challenge the status quo in the pharmaceutical industry.  The two discuss how Tadaaki's time as a surgical oncologist has influenced his leadership style, how collaboration is key for making impacts for patients, the next game changers in cancer treatment and more. A little bit more on EMJ GOLD's guest…  Dr Tadaaki Taniguchi leads Astellas' global team in identifying, discovering and developing new treatments that have the potential to transform healthcare, with a focus on innovative and patient-centred therapies. He has more than 20 years of industry experience spanning research, development and medical affairs, and has worked in a range of therapeutic areas including diabetes and oncology. Prior to joining Astellas, Tadaaki held senior positions at other major pharmaceutical companies in the US, Japan and China. Before joining the industry, he spent 10 years as a surgical oncologist – giving him a unique perspective on how to deliver breakthrough science that changes the way diseases are treated.

In this penultimate episode of Season 7, Isabel and Jade sit down to discuss EMJ GOLD's most recent features of the month – our infographic on optimising pharma's customer experience journey and an article on how exactly to design this experience. Within the episode, the team explore how the industry may be missing out on insights gathered from HCPs, what makes a ‘winning' website for HCPs and more – featuring exclusive input from Robert Tegge, Associate Principal, ZS, who shares valuable insights on what HCPs are really looking for before and after a congress. A little more on EMJ GOLD's guest…  Robert Tegge is a leader within the ZS meetings and events practice area, which focuses on identifying insights to drive improved outcomes for our clients' meetings programs. He collaborates with organizations to help build capabilities and solve unique problems, leveraging ZS's technology and operations infrastructure as well as industry expertise. Robert has a wealth of experience in strategy and operations roles across various healthcare sectors, including providers, pharmaceuticals, and medical products. In these roles, he has consistently leveraged data to provide actionable insights on a variety of sales, marketing, and growth decisions. He also holds a B.S. and an M.S. in civil engineering from the University of Illinois at Urbana-Champaign, and an MBA from Northwestern University's Kellogg School of Management.

In this week's edition of the podcast, Isabel and Jade share an interview with Dr Harmony Garges, Chief Medical Officer, ViiV Healthcare. She speaks with Dr Jonathan Sackier, Host, EMJ Podcast, who joined us in Reuters Barcelona where we meet our guest. Together, the two discuss Harmony's decision to join the pharmaceutical industry, how treating children with HIV needs to be approached differently, her views on improving vital access to HIV treatment and much more. This is the longer version of her Catalyst interview with us, check that out here.

In this week's episode, Danie du Plessis, Executive Vice President, Pharmaceutical Operations, Kyowa Kirin, sits down with the EMJ GOLD team to share the value that patient partnerships can hold in the industry. Danie explores how patient partnerships have evolved over the years, what companies should be doing to get them to their best potential, the value of learning from others and much more. A little more on EMJ GOLD's guest… After completing his medical studies and a Master's Degree in Clinical Pharmacology in South Africa, Danie spent three years working in a primary care setting including his own private practice. He joined the pharmaceutical industry in 1993, worked in medical affairs, marketing and sales, pharmacovigilance and clinical operations. He has held roles such as including Senior Vice President and Head of Worldwide Medical Affairs at GlaxoSmithKline. Danie joined Kyowa Kirin International in August 2019 as head of Medical Affairs and has been Executive Vice President Pharmaceutical Operations since April 2024.  He is also a Director and Chair of the Global non-profit Medical Affairs Professional Society (MAPS) Board, Fellow of the Faculty of Pharmaceutical Medicine in the UK, visiting senior lecturer at King's College, London and an affiliate member of the Association for Professional Executive Coaching and Supervision (APECS). 

Tune in to the latest episode of the EMJ GOLD podcast as Isabel and Jade cross the halfway point of the season with special guest host Dr Jonathan Sackier of the EMJ podcast. In this episode, the team listen back to Jonathan's discussion with Stefan Woxström, Senior Vice President Europe and Canada, AstraZeneca at Reuters Events: Pharma 2024 in Barcelona. Together, the two unpick the current small molecule funding landscape, how to improve incentives to invest in rare diseases, how to better inform policymakers about the difference they can make and much more. A little more on EMJ GOLD's guest… In Stefan's role as SVP Europe and Canada at AstraZeneca, he is dedicated to supporting teams across 30 markets to grow the company ethically and sustainably. His focus is to improve the lives of millions of patients, with a particular emphasis on partnering to find solutions to healthcare challenges, addressing the burden of chronic disease and transforming health systems to be more future-proofed and resilient. He's worked at AstraZeneca for over 28 years, having joined before the merger of Astra and Zeneca in 1999, and holds a BSc and MSc in Business Administration & Economics from Stockholm University. He has additionally sat on the boards of multiple corporations, including The Swedish Chamber of Commerce and Industry in Japan, the EFPIA and most recently the Swedish Swiss Chamber of Commerce.

This week, Claire D'Abreu-Hayling, Chief Scientific Officer, Sandoz, joins Isabel on the podcast to share how leading with love rather than ruling with an iron fist is the best way to get results in the pharmaceutical industry.  In this episode, Claire and Isabel discuss how she fell in love with science as a child, the leadership skills she has gained over the course of her career and the importance of valuing your people and being valued in return.  A little more on EMJ GOLD's guest… Claire D'Abreu-Hayling is the Chief Scientific Officer at Sandoz, and with more than 30 years of experience in the pharmaceutical industry under her belt, she knows a thing or two about life sciences leadership - past and present. At the company Claire oversees the global product development network where she manages infrastructure strategy, pipeline execution and talent acquisition for both small molecules and biosimilars. Outside of work, Claire is a true champion of authenticity in the workplace. She is passionate about diversity, equity and inclusion and is particularly committed to mentoring Black and Asian women who are pursuing careers in STEM.

Join EMJ GOLD for a special edition of the podcast, in which Isabel is joined by Tim Uden, Creative Director, EMJ to discuss the new frontier of medical education tools and skills. In this episode, the two explore how new technological offerings, such as interactive articles, are transforming the space for medical content – enabling content creators to share research in a more impactful way and helping healthcare professionals better engage with and continue their professional development. Check out EMJ's interactive article mentioned in the podcast: JAK inhibitors: a new frontier in dermatology

As we approach the end of Pride month, Jade explores how the pharmaceutical industry can best support staff and patients who identify as part of the LGBTQ+ community. She talks with Edmond Chan, Senior Director, EMEA Therapeutic Area Lead, Haemato-Oncology, J&J, who shares his personal views on how the industry can improve health outcomes and encourage authenticity.  In this interview, they discuss how both the pharmaceutical and healthcare industries can do their best to support people from the LGBTQ+ community, the unique challenges that patients and staff may face and more.   A little more on GOLD's guest…  Edmond has been with J&J for just over ten years, starting in pharmacovigilance before moving into medical affairs. During this time, he has worked in the areas of diabetes and immunology before recently settling into his current area of expertise, haemato-oncology.   Edmond also works as an ABPI final signatory and holds a PhD in Medical Research in Therapeutic Antibodies as well as a Masters in Medical Statistics. He also has 12 years' experience in clinical practice.   At the heart of all these academic and professional achievements, Ed is also a proud member of the LGBTQ+ community and strives to be a role model for other members. 

With Season 7 in full swing, Isabel dives deep into the fascinating world of women's health with Nichole Davies, Chief Strategy Officer, VML, to uncover the truth behind why women live longer but in poorer health and how the industry can incite change. In the interview, they discuss the rise of FemTech, the challenge of funding and reimbursement, the role men can play in moving the conversation up the agenda and more. A little more on GOLD's guest… Nichole leads the strategic disciplines and teams for the global VML Health network, overseeing research and development for all client and agency strategy and messaging. With over 20 years in the healthcare industry, she has worked in cities including London, New York, San Francisco, and Singapore. Nichole previously led strategy for Wunderman Thompson Health, Grey Health and Interbrand Health, following a decade in consulting. Her experience covers diverse areas such as oncology, immunology, rare diseases, respiratory health, women's health, diabetes and nutrition. Nichole has collaborated with industry leaders like AstraZeneca, Pfizer and Johnson & Johnson. Nichole graduated with honors in Chemistry from UMIST and completed her Postgrad in Marketing at London Business School. A Chartered Marketer, she is dedicated to driving change for improved patient outcomes and has worked with the Department of Health on patient communication standards.

The GOLD podcast is back and better than ever! Tune in as Isabel and Jade unveil GOLD's new brand identity 'EMJ GOLD' and enter Season 7 with new energy, new insights and on camera for the first time! But who is the season's first guest? Meet Mercedes Diz, Chief Marketing Officer, Almirall, who spoke to Jade at the Reuters Pharma 2024 event in Barcelona earlier this year. In the interview, Jade asks Mercedes about Almirall's move from respiratory health to dermatology, pushing your limits to achieve your goals and how the industry can work to go beyond the surface to support patients with dermatological concerns. A little more on GOLD's guest… Mercedes Diz has over 20 years' experience in the pharmaceutical industry, having graduated with a degree in Biochemistry and Molecular Biology from the Autonomous University of Madrid. She has worked in a number of different pharmaceutical companies, from J&J to Pfizer, and is also a keen member of the Healthcare Businesswomen's Association. At Almirall, she leads portfolio strategy and commercial innovation for global brands, new products and digital and cultural transformation.

Join Isabel and Jade for this special episode of the GOLD podcast as three of last year's guests share their predictions for the pharmaceutical industry in 2024. The panel includes Matt Lewis from Inizio, Rick Hollis from Ipsen and Claudia Martinez from the Access to Medicine Foundation, all of whom share their predictions in their areas of expertise. But that's not all. The GOLD hosts also reminisce about the team's 2023 predictions podcast to see if these guests could really see the future.

The Season 6 finale of the GOLD podcast has landed! Tune in to hear Isabel and Jade present a discussion with Kinnari Patel, President and Chief Operating Officer, Rocket Pharmaceuticals.  In this episode, Kinnari shares her thoughts on how the industry can engage the next generation of scientific leaders to propel itself into the future. Tune in to find out what might be stopping the younger generation from pursuing a career in pharma and how the industry can work to change their minds, the benefits of a more diverse workforce, the future of drug development and more. If you're interested in learning more about the topic areas discussed in this episode, check out the following content:  Mastering medical affairs Taking women to the top of pharma Do happy employees equal better innovation? Last week's podcast: A patient's right to thrive, not just survive

Tune in to the latest episode of the GOLD podcast which sees Isabel sit down for a chat with Wendy Bartie, Senior Vice President and General Manager, US Hematology and Cell Therapy, Bristol Myers Squibb. In the episode, Wendy discusses her passion for developing life-saving cancer drugs with less toxic side effects. Learn about how far the industry has come, while being guided through the ways in which the sector could still evolve for the benefit of patients. If you're interested in learning more about the topic areas discussed in this episode, check out the following content: Going for gold in gynaecological cancers Mental health matters in pharma's approach to care Last week's podcast: A high-speed chase for oncology innovation

Tune in for a sneak peek of GOLD's latest Catalyst interview with Dr Peter Ahnesorg, Global Hematology Franchise Head, Roche.   In this exclusive teaser of the full interview, Peter talks about why he left research for industry, Roche's commitment to ensuring equitable access to its medicines and what he believes are the qualities of a good leader today.   If you're interested in learning more about the topic areas discussed in this episode, check out the following content: Podcast: Changing the tide on health inequities Podcast: Do happy employees equal better innovation? Last week's podcast: A high-speed chase for oncology innovation

Tune in to the latest episode of the GOLD podcast as Isabel and Jade present a discussion with Jaime Manzanera Gómez, EMEA Brand Director, Oncology, Eisai, who details how oncology teams can best increase the pace of innovation in the field. In this episode, Jaime shares his thoughts on the pace of innovation after the heights of COVID-19, how regulatory constraints can sometimes affect the industry's thirst for innovation, his passion for the outdoors and much more. If you're interested in learning more about the topic areas discussed in this episode, check out the following content:   Do happy employees equal better innovation? Going for gold in gynaecological cancers Last week's podcast: Changing the tide on health inequities

Listen in to the newest episode of the GOLD podcast, in which Jade digs deep into the diversity, equity and inclusion (DE&I) space with Marion Brooks, Vice President and US Country Head, Diversity, Equality and Inclusion, Novartis. In the interview, the pair discuss why Marion left a career in commercial for DE&I, the need for more action on health inequities, Novartis's approach to creating a more diverse medical workforce and much more. If you're interested in learning more about the topic areas discussed in this episode, check out the following content:   Roche's Davidek Herron: My journey with diversity, equity and inclusion 4 top tips to create the perfect ERG Last week's podcast: Why HCPs are losing trust in pharma marketing

Tune in to a new episode of the GOLD podcast as hosts Isabel and Jade discuss a timely topic for the pharmaceutical industry: how to build trust with healthcare professionals. With a recent survey showing that 80% of HCPs don't trust the content the industry produces for them, the team look at the story behind the statistic. They explore where the problems lie and how the industry can improve for the benefit of its customers. GOLD also hears from Rob Verheul, CEO, Graphite Digital, the company behind the report, who shares his takeaways from the research. These include the importance of data accuracy, the value of a good customer experience, top tips for building trust and more. If you're interested in learning more about the topic areas discussed in this episode, check out the following content:    Conquering generational differences in HCP marketing Meeting customer needs in medical affairs Getting to grips with customer experience

Tune in to the latest instalment of the GOLD podcast, which sees Isabel and Jade present a conversation with Rick Hollis, Director of Business Excellence, Ipsen, about his views on how the pharmaceutical industry's customer engagement model needs to grow and evolve. Discover the highs and lows of creating meaningful marketing interactions with this week's guest as Rick explores the evolution of customer engagement, his top tips for creating more enticing communications, his vision for a customer experience utopia and more. If you're interested in learning more about the topic areas discussed in this episode, check out the following content:   Upgrading the personal touch in CX Getting to grips with customer engagement Last week's podcast: Investigating the reality of rare disease research

Tune into to this bonus episode and enjoy an exclusive preview of GOLD's latest catalyst interview with Dr Andreas Konieczny, Vice President and Head of Medical Affairs Europe, ImmunoGen.   In this teaser of the full interview, Isabel and Jade digest Andreas's thoughts on using medical affairs teams to drive drug launches, how to help different personalities work in harmony and how to gain leadership skills through the power of observation.   If you're interested in learning more about the topic areas discussed in this episode, check out the following content: Revealing the true value of medical affairs Last week's podcast: Do happy employees equal better innovation?

Discover the reality behind the expectations of rare disease research and drug development with Isabel and Jade as they present a discussion with Dr Ian Winburn, Vice President, Global Lead for Rare Hematology, Pfizer.   Tune in to hear Ian and Isabel discuss the current pharmaceutical landscape for rare diseases, including discussions around clinical trials, partnering early in the drug lifecycle, what the industry should be keeping in mind for the future of the field and much more.    If you're interested in learning more about the topic areas discussed in this episode, check out the following content: Mitigating the rare disease RWD deficit Last week's podcast: Do happy employees equal better innovation

Tune in to the latest episode of the GOLD podcast as Nate Cope, Chief Operating Officer, Otsuka Europe, details how companies can drive innovation by being a great place to work. In this episode, Nate reveals the story behind his passion for prioritising people, what companies should and shouldn't do in their mission to become more people-centric and an example of how Otsuka sought to reward its employees for getting better sleep. If you're interested in learning more about the topic areas discussed in this episode, check out the following content: 4 top tips to create the perfect ERG The driving seat of organisational change Last week's podcast: Taking the pulse of digital health

The GOLD podcast is back on the airwaves! Join Isabel and Jade every Tuesday as they speak to a new bunch of inspiring leaders from the pharmaceutical industry.   The first interviewee of the season is Parveen Jayia, Therapy Area Head, Breast and Gynaecological Cancers, AstraZeneca, who talks to GOLD about the role digital health can play in the future of the industry. From working with policymakers to designing the perfect digital health strategy, tune in to hear her top tips for staying ahead of the curve. If you're interested in learning more about the topic areas discussed in this episode, check out the following content: AI, ChatGPT and modernising medical affairs Inspiring innovation and the future of digital therapeutics Going for gold in gynaecological cancers The opinions and views expressed here are her personal and do not necessarily reflect the opinions or views of AstraZeneca or any subsidiary thereof.

In this final GOLD Nugget of the series, Jade reflects on her conversation with season finale guest Christy Seigel, General Manager, Breast and Women's Cancers Portfolio, Novartis US Oncology, from her episode ‘Going the extra mile for patients with disabilities'.  In this episode, Jade picks out her favourite anecdote Christy shared, which was how her experience of raising children with disabilities helped her to push for better disability inclusion within the pharmaceutical industry.  If you're interested in learning more about the topic areas discussed in this episode, check out the following content:   Christy's full episode: Season finale: Going the extra mile for patients with disabilities - GOLD (emg-gold.com)  Going for gold in gynaecological cancers  

It is time for the third ‘GOLD nugget' from Season 5, and Jade is highlighting her favourite insight shared by Sarah Jarvis, Global Lead for the Medical Consulting Practice, ZS, from her episode with colleague Sunil John, ‘Meeting customer needs in medical affairs'.   In this clip, Sarah shares findings from ZS's latest Medical Affairs Outlook report and details what medical education healthcare professionals want from the industry at each phase of the product lifecycle.  If you're interested in learning more about the topic areas discussed in this episode, check out the following content:    Sarah's full episode: https://www.emg-gold.com/post/meeting-customer-needs-in-medical-affairs  Revealing the true value of medical affairs: https://www.emg-gold.com/post/revealing-the-true-value-of-medical-affairs